Skip to content
Aperlena
Language:

Germany - Medicines - Open-House-Original rebate agreements 2026-13 Etrasimod

Original Deutschland - Arzneimittel - Open-House-Originale-Rabattverträge 2026-13 Etrasimod

Open Contract notice 769 days left
Watch this tender

Deadline 31 Oct. If it moves, an email when the register sees it. A correction: the same email. Your plan: decide by 17 Oct, questions by 17 Oct, draft by 24 Oct. Log in

  1. Published
  2. Today
  3. Deadline open for 776 days
  4. Awarded pending

The Aperlena Verdict

Incumbent-locked

Siehe im Feld "Allgemeine Informationen" has won 6 of the last 6 comparable contracts from this buyer over 5 years. Winning here means displacing an incumbent, so price the effort accordingly.

Based on 6 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.

Summary

Machine-generated summary

Participating German statutory health insurers intend to conclude rebate agreements for the active substance Etrasimod under § 130c(1) SGB V. The procedure is an Open-House-Original arrangement: no individual negotiations take place and uniform conditions apply. No exclusivity is granted to any contracting partner. Contracts run for a maximum of 24 months from 01.11.2026 and end at the latest on 31.10.2028, regardless of the signing date. If the patent or market exclusivity expires earlier, the contract ends automatically at the end of that month. Joining the arrangement is possible at any time during the contract term. Details are in the participation and contract documents.

Description

Die beteiligten Kassen verfolgen das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zu dem Wirkstoff Etrasimod zu schließen. Der Vertragsschluss erfolgt im Rahmen des Open-House-Originale-Verfahrens der beteiligten Kassen: Individuelle Verhandlungen über Vertragsinhalte werden nicht geführt, es gelten einheitliche Konditionen. Die beteiligten Krankenkassen sichern einzelnen Vertragspartnern keine Exklusivität zu. Die Vertragslaufzeit beträgt maximal 24 Monate beginnend mit dem 01.11.2026. Der Vertrag endet spätestens am 31.10.2028, unabhängig vom Datum des Vertragsschlusses. Bei Patentablauf/Ablauf der Marktexklusivität vor dem o.g. Enddatum endet der Vertrag automatisch mit Ablauf des Monats des Patentablaufs/der Marktexklusivität. Ein Beitritt zu diesem Open-House-Originale-Verfahren ist innerhalb der Vertragslaufzeit jederzeit möglich. Alle weiteren Informationen sind den Teilnahme- und Vertragsunterlagen zu entnehmen. Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130c Abs. 1 SGB V zu dem Wirkstoff Etrasimod im Rahmen eines Open-House-Verfahrens.

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 8 hours ago

View the official notice

More from this buyer

Full buyer profile

45 open tenders right now

Who usually wins this buyer's contracts in this sector

Company Wins Total awarded Last win
Siehe im Feld "Allgemeine Informationen" 6 n/a Sep 2026

Based on 6 awards with a linked company profile over the last 5 years.

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€10,028,743
9,662 open across Europe right now
Buyer track record on Aperlena
163 notices tracked · 54 awarded
€14 in awarded contracts

Never miss a tender like this

69 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

769 days left

Source

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close